Freeline Therapeutics Holdings plc reported unaudited consolidated earnings results for the six months ended June 30, 2021. For the period, the company reported loss from operations of $72,747,000 against $41,108,000 a year ago. Net loss was $74,815,000 or $2.10 per basic and diluted share against $33,264,000 or $3.51 per basic and diluted share a year ago.